GSK and Theravance announce regulatory submission for ANORO™ (UMEC/VI) in Europe

GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the submission of a regulatory application in the European Union for the investigational once-daily LAMA/LABA combination medicine, UMEC/VI, for patients with chronic obstructive pulmonary disease (COPD).
Source: GSK news - Category: Pharmaceuticals Source Type: news